Bio Vantage

How Much Should You Pay For Incyte?

Incyte (NASDAQ:INCY) is a mid-cap biopharmaceutical company that develops kinase inhibitors with broad applications for cancers and inflammatory diseases. The unique aspect of this company is that it has secured several corporate partners to co-develop its drug candidates. While the partnership validates its business strategy, one might ask whether Incyte has traded off its huge revenue upside with modest but secured royalty streams. It is no wonder that Street analysts have issued a wide range of price targets for INCY (high $36, low $14). Currently trading at around $19-$20 with a $2.7B market cap, how do we know if it is under-valued or over-valued? We decided to cover Incyte in a 3-part report to address several key issues....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details